Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: A Randomized Trial Comparing Sirolimus and Tacrolimus

Calcineurin inhibitors have decreased acute rejection and improved early renal allograft survival, but their use has been implicated in the development of chronic nephrotoxicity. We performed a prospective, randomized trial in kidney transplantation comparing sirolimus‐MMF‐prednisone to tacrolimus‐MMF‐prednisone. Eighty‐one patients in the sirolimus group and 84 patients in the tacrolimus group were enrolled (mean follow‐up = 33 months; range 13–47 months). At 1 year, patient survival was similar in the groups (98% with sirolimus, 96% with tacrolimus; p = 0.42) as was graft survival (94% sirolimus vs. 92% tacrolimus, p = 0.95). The incidence of clinical acute rejection was 10% in the tacrolimus group and 13% in the sirolimus group (p = 0.58). There was no difference in mean GFR measured by iothalamate clearance between the tacrolimus and sirolimus groups at 1 year (61 ± 19 mL/min vs. 63 ± 18 mL/min, p = 0.57) or 2 years (61 ± 17 mL/min vs. 61 ± 19 mL/min, p = 0.84). At 1 year, chronicity using the Banff schema showed no difference in interstitial, tubular or glomerular changes, but fewer chronic vascular changes in the sirolimus group. This study shows that a CNI‐free regimen using sirolimus‐MMF‐prednisone produces similar acute rejection rates, graft survival and renal function 1–2 years after transplantation compared to tacrolimus‐MMF‐prednisone.

[1]  S. Head,et al.  De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  P. Tesch,et al.  Insulin facilitation of muscle protein synthesis following resistance exercise in hindlimb-suspended rats is independent of a rapamycin-sensitive pathway. , 2004, American journal of physiology. Endocrinology and metabolism.

[3]  T. Lømo,et al.  NFAT is a nerve activity sensor in skeletal muscle and controls activity-dependent myosin switching. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Paavonen,et al.  Sirolimus‐Based Therapy Following Early Cyclosporine Withdrawal Provides Significantly Improved Renal Histology and Function at 3 Years , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  T. Larson,et al.  WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS1 , 2004, Transplantation.

[6]  A. Gaber,et al.  COMPARISON OF SIROLIMUS-BASED CALCINEURIN INHIBITOR-SPARING AND CALCINEURIN INHIBITOR-FREE REGIMENS IN CADAVERIC RENAL TRANSPLANTATION , 2004, Transplantation.

[7]  Joseph P Grande,et al.  Correlation of Quantitative Digital Image Analysis with the Glomerular Filtration Rate in Chronic Allograft Nephropathy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  L. Gesualdo,et al.  EARLY WITHDRAWAL OF CYCLOSPORINE IMPROVES 1-YEAR KIDNEY GRAFT STRUCTURE AND FUNCTION IN SIROLIMUS-TREATED PATIENTS: RESPONSE TO THE AUTHORS , 2004 .

[9]  D. Hricik,et al.  Comparison of Sirolimus vs. Mycophenolate Mofetil on Surgical Complications and Wound Healing in Adult Kidney Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  S. Chueh,et al.  Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1 , 2003, Transplantation.

[11]  C. Troppmann,et al.  Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study , 2003, Transplantation.

[12]  H. Blom,et al.  J Am Soc Nephrol 14: 1880–1888, 2003 Improved Cardiovascular Risk Profile and Renal Function in Renal Transplant Patients after Randomized Conversion from , 2022 .

[13]  B. Fivush,et al.  Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study , 2003, Pediatric transplantation.

[14]  W. A. Jurewicz.  Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  S. Jensik,et al.  Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1 , 2003, Transplantation.

[16]  L. Gesualdo,et al.  Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients , 2003, Transplantation.

[17]  A. Novick,et al.  Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1 , 2002, Transplantation.

[18]  T. Larson,et al.  Subclinical Rejection in Tacrolimus-Treated Renal Transplant Recipients , 2002, Transplantation.

[19]  E. Calabria,et al.  A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  W. Bennett,et al.  Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies , 2001, Current opinion in critical care.

[21]  S. Hariharan.  Long-term kidney transplant survival. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  G. Yancopoulos,et al.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo , 2001, Nature Cell Biology.

[23]  A. Macdonald.  A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS , 2001, Transplantation.

[24]  Barry D Kahan,et al.  Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study , 2000, The Lancet.

[25]  R. Calne,et al.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. , 1999, Transplantation.

[26]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[27]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[28]  Cecka Jm.  The UNOS Scientific Renal Transplant Registry. , 1999 .

[29]  J. Cecka.  The UNOS Scientific Renal Transplant Registry. , 1999, Clinical transplants.

[30]  T. Larson,et al.  GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  D. Rush,et al.  Sequential protocol biopsies in renal transplant patients. Clinico-pathological correlations using the Banff schema. , 1995, Transplantation.

[32]  D. Rush,et al.  Histological findings in early routine biopsies of stable renal allograft recipients. , 1994, Transplantation.

[33]  M. Henry,et al.  Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. , 1993, Transplantation proceedings.

[34]  Y. Akselband,et al.  Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. , 1991, Transplantation proceedings.